Entecavir Post-Marketing Surveillance Study To Track Cancer Risk

Entecavir preclinical carcinogenicity studies exhibit an increased risk of tumors in rodents. Bristol-Myers Squibb's proposed post-marketing study may not be long enough to track cancers with long latency, FDA says. Advisory committee will review entecavir for treatment of hepatitis B on March 11.